MEDiC Life Sciences develops a next-generation functional genomics platform (MCAT™) that measures millions of gene-to-drug interactions and identifies SLS™ biomarkers to improve cancer drug response and expand market potential. The company uses 3D tumor models to increase the accuracy and translatability of target and biomarker discovery for solid tumors. MEDiC partners with pharmaceutical companies including Bristol Myers Squibb and Hanmi to deliver biomarkers and targets to enhance oncology pipelines and pursue clinical validation collaborations. The new $5M strategic investment from LG and Hanmi will be used to accelerate adoption of its technology, bolster business development, and advance early drug discovery efforts. MEDiC previously raised an $8M seed led by a group including Illumina Accelerator, Top Harvest Capital, Primer Sazze, Big Basin Capital, First In Ventures, Valuence Ventures, Gradient, and Wing Venture Capital. Founded in 2020 and based in Mountain View, California, the company is co‑founded by CEO Kyuho Han, Ph.D., and CTO Hong‑Pyo Lee.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024